The prospective, double-blind, randomized controlled trial (RCT) enrolled 244 patients to evaluate the Butterfly Prostatic Retraction Device, a minimally invasive, reversible implant that mechanically ...

Butterfly Medical announced that it completed the final 12-month follow-up for all patients in a study of its prostatic ...

This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...

CHAD Thompson grappled with a silent problem for 20 years – he couldn’t pee properly, and it was a constant source of anxiety ...

Research supports that both finasteride and dutasteride help treat hair loss, particularly when caused by androgenetic ...

Stemcell United Ltd. ( (AU:BP8)) has provided an announcement. BPH Global Ltd, listed on the ASX under ticker BP8, has reported a change in its issued capital structure following the expiry of certain ...

Stemcell United Ltd. ( (AU:BP8)) has issued an update. BPH Global Ltd has announced the issuance of 60,000,000 unquoted options, set to expire on December 2, 2027, with an exercise price of $0.006.

In a trial, the newly approval urethral stent provided significant and durable relief of BPH-related LUTS over 12 months. The FDA has approved the ProVee® System for treatment of benign prostatic ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...